$ABL
Abacus Life, Inc. Stock $abl

$abl Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000181428724000054 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$28.15M
YoY Change		33.27%
Cost Of Revenue		$2.188M
YoY Change		-34.98%
Gross Profit		$25.96M
YoY Change		46.21%
Gross Profit Margin		92.23%
Selling, General & Admin		$17.66M
YoY Change		52.98%
% of Gross Profit		68.02%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$1.745M
YoY Change		2.98%
% of Gross Profit		6.72%
Operating Expenses		$19.11M
YoY Change		66.82%
Operating Profit		$6.850M
YoY Change		8.73%
Interest Expense		-$3.191M
YoY Change		-219.11%
% of Operating Profit		-46.59%
Other Income/Expense, Net		-$12.39M
YoY Change		249.99%
Pretax Income		-$5.535M
YoY Change		-300.55%
Income Tax		-$250.4K
% Of Pretax Income
Net Earnings		-$5.125M
YoY Change		-667.33%
Net Earnings / Revenue		-18.21%
Basic Earnings Per Share		-$0.07
Diluted Earnings Per Share		-$0.07
COMMON SHARES
Basic Shares Outstanding	74.68M shares	74.65M shares
Diluted Shares Outstanding		74.69M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$22.43M
YoY Change		-38.72%
Cash & Equivalents		$19.41M
Short-Term Investments		$3.019M
Other Short-Term Assets		$2.071M
YoY Change		107.09%
Inventory
Prepaid Expenses
Receivables		$3.595M
Other Receivables		$2.702M
Total Short-Term Assets		$30.80M
YoY Change		-22.07%
LONG-TERM ASSETS
Property, Plant & Equipment		$888.5K
YoY Change		239.28%
Goodwill		$139.9M
YoY Change		-0.25%
Intangibles		$24.65M
YoY Change		-21.03%
Long-Term Investments		$277.4M
YoY Change		202.13%
Other Assets		$1.651M
YoY Change		65.07%
Total Long-Term Assets		$446.5M
YoY Change		68.63%
TOTAL ASSETS
Total Short-Term Assets		$30.80M
Total Long-Term Assets		$446.5M
Total Assets		$477.3M
YoY Change		56.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses		$2.535M
YoY Change		298.14%
Deferred Revenue		$924.1K
YoY Change		164.9%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$13.73M
YoY Change
Total Short-Term Liabilities		$23.86M
YoY Change		337.23%
LONG-TERM LIABILITIES
Long-Term Debt		$166.5M
YoY Change		40.16%
Other Long-Term Liabilities		$16.99M
YoY Change		399.73%
Total Long-Term Liabilities		$183.5M
YoY Change		50.17%
TOTAL LIABILITIES
Total Short-Term Liabilities		$23.86M
Total Long-Term Liabilities		$183.5M
Total Liabilities		$219.4M
YoY Change		58.72%
SHAREHOLDERS EQUITY
Retained Earnings		-$39.64M
YoY Change		39.07%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$258.0M
YoY Change
Total Liabilities & Shareholders Equity		$477.3M
YoY Change		56.85%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$5.125M
YoY Change		-667.33%
Depreciation, Depletion And Amortization		$1.745M
YoY Change		2.98%
Cash From Operating Activities		-$52.28M
YoY Change		307.84%
INVESTING ACTIVITIES
Capital Expenditures		$242.6K
YoY Change		142.55%
Acquisitions
YoY Change
Other Investing Activities		-$208.5K
YoY Change		-102.14%
Cash From Investing Activities		-$451.1K
YoY Change		-104.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-19.18M
YoY Change		-199.78%
NET CHANGE
Cash From Operating Activities		-52.28M
Cash From Investing Activities		-451.1K
Cash From Financing Activities		-19.18M
Net Change In Cash		-71.91M
YoY Change		-548.62%
FREE CASH FLOW
Cash From Operating Activities		-$52.28M
Capital Expenditures		$242.6K
Free Cash Flow		-$52.53M
YoY Change		306.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	City Area Code CityAreaCode	800
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	998945	usd
CY2024Q3	us-gaap	Assets Assets	477309168	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	413071	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	924083	usd
CY2024Q3	abl	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	2600000	usd
CY2024Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	23862348	usd
CY2024Q3	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	26967575	usd
CY2023Q3	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	18926144	usd
	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	73778331	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	165340772	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	257939628	usd
	dei	Entity Registrant Name EntityRegistrantName	Abacus Life, Inc.
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32835
	dei	Local Phone Number LocalPhoneNumber	561-4148
CY2023Q3	us-gaap	Revenues Revenues	21120930	usd
	us-gaap	Revenues Revenues	42705904	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	256849488	usd
	us-gaap	Gross Profit GrossProfit	37877997	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1704154	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6651942	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15489503	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	164070076	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001814287
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1210472
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74678769	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19409615	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25588668	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3019055	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2252891	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	1050972	usd
	us-gaap	Profit Loss ProfitLoss	-5908533	usd
CY2024Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2702103	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2070875	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	699127	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	31776834	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	888519	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	400720	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24653141	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29623130	usd
CY2024Q3	us-gaap	Goodwill Goodwill	139930190	usd
CY2023Q4	us-gaap	Goodwill Goodwill	140287000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2033538	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1893659	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1071172	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	273249493	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	122296559	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1185740	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1105935	usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1850000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1650000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1650698	usd
CY2024Q3	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	0	usd
CY2023Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	96107	usd
CY2023Q4	us-gaap	Assets Assets	331826067	usd
	us-gaap	Revenues Revenues	78711777	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7652412	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4827907	usd
	us-gaap	Gross Profit GrossProfit	71059365	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41396346	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11113382	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-4036327	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-309865	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1220161	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	491356	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	856744	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5177785	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1696994	usd
	us-gaap	Operating Expenses OperatingExpenses	55185495	usd
	us-gaap	Operating Expenses OperatingExpenses	15745884	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	15873870	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	22132113	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8487040	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	12417946	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3620695	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1670828	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	71283	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	132610	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1565	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19101548	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4494377	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-3227678	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	17637736	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2238419	usd
	us-gaap	Profit Loss ProfitLoss	-5908533	usd
	us-gaap	Profit Loss ProfitLoss	15399317	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-204716	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-339692	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5703817	usd
	us-gaap	Net Income Loss NetIncomeLoss	15739009	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6009289	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	14151307	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-229820	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-635041	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5779469	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14786348	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	553953	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	570602	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	605268	usd
CY2024Q3	abl	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	623490	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2941007	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	667200	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2273807	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5125055	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	903361	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5703817	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15739009	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74694319	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63349823	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54632826	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5125055	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54632826	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5125055	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	903361	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5703817	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	903361	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5703817	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15739009	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5125055	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15739009	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5125055	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	903361	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5703817	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15739009	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74694319	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63349823	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54632826	shares
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	903361	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5703817	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15739009	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74694319	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63349823	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66984401	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54632826	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74694319	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63349823	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66984401	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54632826	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74694319	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63349823	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66984401	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54632826	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2101 Park Center Drive, Suite 200
CY2024Q3	us-gaap	Assets Current AssetsCurrent	30796677	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	13730026	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	13029632	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2535277	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4354225	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118058	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	507000	usd
CY2023Q4	abl	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	0	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	751734	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23326331	usd
CY2024Q3	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	96358740	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	55318923	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1860736	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1796727	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12003461	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	9199091	usd
CY2024Q3	abl	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	15130000	usd
CY2023Q4	abl	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	6642960	usd
CY2024Q3	us-gaap	Liabilities Liabilities	219369540	usd
CY2023Q4	us-gaap	Liabilities Liabilities	167755991	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1048226	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	146650	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	12025137	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1283062	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	309655378	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	199826278	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39639373	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34726135	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	32721	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	108373	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-91537	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	138283	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	257939628	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	164070076	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	477309168	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	331826067	usd
	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	39921061	usd
CY2024Q3	us-gaap	Revenues Revenues	28148491	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	2187981	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	3364957	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	25960510	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	17755973	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2169197	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3116999	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9838951	usd
CY2024Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-124237	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2088797	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	417677	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-306800	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1745279	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1694853	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	19110539	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	11455961	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	6849971	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	6300012	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8766500	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4218314	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2679237	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	609496	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	63826	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9832	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20086	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12385150	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3538725	usd
CY2024Q3	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-5535179	usd
CY2023Q3	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	2761287	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-250368	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1710315	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2680855	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-5284811	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	1050972	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-159756	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	147611	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-5125055	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	903361	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74694319	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63349823	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66984401	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54632826	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74694319	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63349823	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66984401	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54632826	shares
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-5284811	usd
	us-gaap	Profit Loss ProfitLoss	15399317	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-53656	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-1016034	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-111835	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-1248010	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	-11079	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	0	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	-11079	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	0	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5327388	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	34938	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-170730	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3089077	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-751734	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	109702614	usd
	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	55516357	usd
	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	-626006	usd
	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	5601493	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-116827478	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50232674	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	593459	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	96721	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	102136	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	200000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	350000	usd
	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	-271571	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1167166	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1887460	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	92000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7213627	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10742075	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	483451	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	10841551	usd
	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	0	usd
	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	23533073	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6852207	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	abl	Proceeds Received From Spac Trust ProceedsReceivedFromSPACTrust	0	usd
	abl	Proceeds Received From Spac Trust ProceedsReceivedFromSPACTrust	972262	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111815591	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54259604	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6179053	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6596367	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25588668	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30052823	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19409615	usd
	us-gaap	Interest Paid Net InterestPaidNet	7851024	usd
	us-gaap	Interest Paid Net InterestPaidNet	1330323	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2691871	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	abl	Noncash Sale Of Life Settlement Policies At Fair Value NoncashSaleOfLifeSettlementPoliciesAtFairValue	14294275	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-91292	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5156658	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	126230	usd
CY2024Q1	abl	Stockholders Equity Deferred Transaction Costs StockholdersEquityDeferredTransactionCosts	483451	usd
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	7524392	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6093371	usd
CY2024Q1	abl	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	4453203	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	7436	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1275471	usd
CY2024Q2	abl	Stockholders Equity Deferred Transaction Costs StockholdersEquityDeferredTransactionCosts	-790579	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	92000000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7213627	usd
CY2024Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	3217683	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6165459	usd
CY2024Q2	abl	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	2397854	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-65615	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	651749	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6416378	usd
CY2024Q3	abl	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1150	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-53656	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	-11079	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-5284811	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28149697	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-112313	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	7624796	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35662180	usd
CY2023Q2	us-gaap	Dividends Dividends	34451607	usd
CY2023Q2	abl	Stockholders Equity Deferred Transaction Costs StockholdersEquityDeferredTransactionCosts	10841551	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	960900	usd
CY2023Q2	abl	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	-2796225	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	165361332	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-119663	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	6723549	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	160498915	usd
CY2023Q3	abl	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	0	usd
CY2023Q3	abl	Adjustments To Additional Paid In Capital Increase From Spac Trust Proceeds AdjustmentsToAdditionalPaidInCapitalIncreaseFromSPACTrustProceeds	972262	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4583632	usd
CY2023Q3	abl	Noncontrolling Interest Increase From Transfer Of Noncontrolling Interest NoncontrollingInterestIncreaseFromTransferOfNoncontrollingInterest	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodAfterTax	-1016034	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	1050972	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166089747	usd
	us-gaap	Profit Loss ProfitLoss	-5908533	usd
	us-gaap	Profit Loss ProfitLoss	15399317	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5177785	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1696994	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	18675208	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4583632	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	638089	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	133211	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1220161	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	491356	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	856744	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Life Settlement Contracts Fair Value Method Unrealized Gain Loss LifeSettlementContractsFairValueMethodUnrealizedGainLoss	38140038	usd
	us-gaap	Life Settlement Contracts Fair Value Method Unrealized Gain Loss LifeSettlementContractsFairValueMethodUnrealizedGainLoss	14259665	usd
	abl	Noncash Gain Loss On Life Settlement Contract Trading NoncashGainLossOnLifeSettlementContractTrading	3110282	usd
	abl	Noncash Gain Loss On Life Settlement Contract Trading NoncashGainLossOnLifeSettlementContractTrading	0	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-4036327	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-309865	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8487040	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
	us-gaap	Interest Income Operating Paid In Kind InterestIncomeOperatingPaidInKind	79805	usd
	us-gaap	Interest Income Operating Paid In Kind InterestIncomeOperatingPaidInKind	0	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3985966	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1743079	usd
	abl	Operating Lease Right Of Use Asset Noncash Income Expense OperatingLeaseRightOfUseAssetNoncashIncomeExpense	-219143	usd
	abl	Operating Lease Right Of Use Asset Noncash Income Expense OperatingLeaseRightOfUseAssetNoncashIncomeExpense	721	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-1406848	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	112559	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	83321	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	929020	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	3989	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-29199	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1371748	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	325294	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2702103	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	651753	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	521850	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-38014	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1818948	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	112388	usd
	abl	Increase Decrease In Accrued Transaction Costs IncreaseDecreaseInAccruedTransactionCosts	2600000	usd
	abl	Increase Decrease In Accrued Transaction Costs IncreaseDecreaseInAccruedTransactionCosts	-908256	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	417083	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-632381	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	259157	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3089077	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-751734	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	109702614	usd
	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	55516357	usd
	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	-626006	usd
	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	5601493	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-116827478	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50232674	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	593459	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	96721	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	102136	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	200000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	350000	usd
	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	-271571	usd
	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	3016158	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1167166	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2569437	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1887460	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	92000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7213627	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10742075	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	483451	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	10841551	usd
	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	0	usd
	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	23533073	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6852207	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	abl	Proceeds Received From Spac Trust ProceedsReceivedFromSPACTrust	0	usd
	abl	Proceeds Received From Spac Trust ProceedsReceivedFromSPACTrust	972262	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111815591	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54259604	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6179053	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6596367	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25588668	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30052823	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19409615	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36649190	usd
	us-gaap	Interest Paid Net InterestPaidNet	7851024	usd
	us-gaap	Interest Paid Net InterestPaidNet	1330323	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2691871	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	abl	Noncash Sale Of Life Settlement Policies At Fair Value NoncashSaleOfLifeSettlementPoliciesAtFairValue	14294275	usd
	abl	Noncash Sale Of Life Settlement Policies At Fair Value NoncashSaleOfLifeSettlementPoliciesAtFairValue	0	usd
	abl	Noncash Purchase Of Life Settlement Policies At Fair Value NoncashPurchaseOfLifeSettlementPoliciesAtFairValue	14294275	usd
	abl	Noncash Purchase Of Life Settlement Policies At Fair Value NoncashPurchaseOfLifeSettlementPoliciesAtFairValue	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14pt">BASIS OF PRESENTATION</span><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements (“Interim Financial Statements”) are presented in accordance with the rules and regulations of the United States ("U.S.") Securities and Exchange Commission ("SEC") and do not include all of the disclosures normally required by U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) as contained in the Company’s Annual Report on Form 10-K. We have condensed or omitted certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP. Accordingly, the consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 21, 2024, as amended by Amendment No. 1 on Form 10-K/A, filed with the SEC on May 30, 2024, and as amended by Amendment No. 2 on Form 10-K/A, filed with the SEC on June 12, 2024 (“2023 Annual Report”). Refer to Note 2 in the Company’s 2023 Annual Report for the full list of the Company’s significant accounting policies. The details in those notes have not changed, except as discussed in Note 2 to the Interim Financial Statements and as a result of normal adjustments in the interim periods. Capitalized terms used and not specifically defined herein have the same meanings given those terms in our 2023 Annual Report. We also may use certain other terms that are defined within these Interim Financial Statements.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Interim Financial Statements presented herein and discussed below include 100% of the assets, liabilities, revenues, expenses, and cash flows of Abacus Life, Inc., (the “Company”) all entities in which the Company has a controlling voting interest (“subsidiaries”), and variable interest entities (“VIEs”) for which the Company is the primary beneficiary, as determined in accordance with consolidation accounting guidance. References in these Interim Financial Statements to net income or loss attributable to common stockholders and stockholders’ equity do not include noncontrolling interests, which represent the outside ownership of our consolidated non-wholly owned entity and are reported separately. Intercompany accounts and transactions between consolidated entities have been eliminated in consolidation.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Interim Financial Statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2024, and the consolidated statements of operations and comprehensive (loss) income for the three and nine months ended September 30, 2024 and 2023, and the consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023. The Interim Financial Statements are not necessarily indicative of the results to be expected for the full year, or any other period. All references to financial information in the Interim Financial Statements in the condensed notes to Interim Financial Statements are unaudited.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, cost of revenue, life settlement policy valuation, goodwill and intangibles valuation, market-indexed note valuation, and income taxes. The uncertainties in the broader macroeconomic environment have made it more challenging to make these estimates. Actual results could differ from our estimates, and such differences may be material.</span></div>
	abl	Noncash Sale Of Life Settlement Policies At Fair Value NoncashSaleOfLifeSettlementPoliciesAtFairValue	0	usd
	abl	Noncash Purchase Of Life Settlement Policies At Fair Value NoncashPurchaseOfLifeSettlementPoliciesAtFairValue	14294275	usd
	abl	Noncash Purchase Of Life Settlement Policies At Fair Value NoncashPurchaseOfLifeSettlementPoliciesAtFairValue	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14pt">BASIS OF PRESENTATION</span><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements (“Interim Financial Statements”) are presented in accordance with the rules and regulations of the United States ("U.S.") Securities and Exchange Commission ("SEC") and do not include all of the disclosures normally required by U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) as contained in the Company’s Annual Report on Form 10-K. We have condensed or omitted certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP. Accordingly, the consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 21, 2024, as amended by Amendment No. 1 on Form 10-K/A, filed with the SEC on May 30, 2024, and as amended by Amendment No. 2 on Form 10-K/A, filed with the SEC on June 12, 2024 (“2023 Annual Report”). Refer to Note 2 in the Company’s 2023 Annual Report for the full list of the Company’s significant accounting policies. The details in those notes have not changed, except as discussed in Note 2 to the Interim Financial Statements and as a result of normal adjustments in the interim periods. Capitalized terms used and not specifically defined herein have the same meanings given those terms in our 2023 Annual Report. We also may use certain other terms that are defined within these Interim Financial Statements.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Interim Financial Statements presented herein and discussed below include 100% of the assets, liabilities, revenues, expenses, and cash flows of Abacus Life, Inc., (the “Company”) all entities in which the Company has a controlling voting interest (“subsidiaries”), and variable interest entities (“VIEs”) for which the Company is the primary beneficiary, as determined in accordance with consolidation accounting guidance. References in these Interim Financial Statements to net income or loss attributable to common stockholders and stockholders’ equity do not include noncontrolling interests, which represent the outside ownership of our consolidated non-wholly owned entity and are reported separately. Intercompany accounts and transactions between consolidated entities have been eliminated in consolidation.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Interim Financial Statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2024, and the consolidated statements of operations and comprehensive (loss) income for the three and nine months ended September 30, 2024 and 2023, and the consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023. The Interim Financial Statements are not necessarily indicative of the results to be expected for the full year, or any other period. All references to financial information in the Interim Financial Statements in the condensed notes to Interim Financial Statements are unaudited.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, cost of revenue, life settlement policy valuation, goodwill and intangibles valuation, market-indexed note valuation, and income taxes. The uncertainties in the broader macroeconomic environment have made it more challenging to make these estimates. Actual results could differ from our estimates, and such differences may be material.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Certain prior period amounts have been reclassified to conform to current presentation.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Certain prior period amounts have been reclassified to conform to current presentation.</span></div>
CY2024Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	2600000	usd
CY2024Q3	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	69729	usd
CY2023Q3	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	1817764	usd
	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	577122	usd
	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	18473597	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	26897846	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	17108380	usd
	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	73201209	usd
	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	21447464	usd
CY2024Q3	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	26967575	usd
CY2023Q3	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	18926144	usd
	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	73778331	usd
	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	39921061	usd
CY2024Q3	us-gaap	Revenues Revenues	28148491	usd
CY2024Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	2600000	usd
CY2024Q3	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	69729	usd
CY2023Q3	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	1817764	usd
	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	577122	usd
	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	18473597	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	26897846	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	17108380	usd
	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	73201209	usd
	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	21447464	usd
CY2024Q3	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	26967575	usd
CY2023Q3	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	18926144	usd
	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	39921061	usd
CY2024Q3	us-gaap	Revenues Revenues	28148491	usd
CY2023Q3	us-gaap	Revenues Revenues	21120930	usd
	us-gaap	Revenues Revenues	78711777	usd
	us-gaap	Revenues Revenues	42705904	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	924083	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	507000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	924083	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	507000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	507000	usd
CY2024Q3	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	532	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	527	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	5	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	976761831	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	273249493	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	2225000	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1071172	usd
CY2023Q4	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	296	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	287	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	9	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	520503710	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	122296559	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	33900000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2023Q3	us-gaap	Revenues Revenues	21120930	usd
	us-gaap	Revenues Revenues	78711777	usd
	us-gaap	Revenues Revenues	42705904	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	924083	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	507000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	924083	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	507000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	507000	usd
CY2024Q3	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	532	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	527	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	5	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	976761831	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	273249493	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	2225000	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1071172	usd
CY2023Q4	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	296	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	287	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	9	insurance_contract
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	520503710	usd
CY2023Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	122296559	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	33900000	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear	7	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMethodFaceValueMaturingInRemainderOfFiscalYear	8100000	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Remainder Of Fiscal Year LifeSettlementContractFairValueMethodNetDeathBenefitMaturityRemainderOfFiscalYear	8100000	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMaturingInRemainderOfFiscalYear	6386561	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInNextTwelveMonths	15	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodFaceValueMaturingInNextTwelveMonths	16908593	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year One LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearOne	19557874	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMaturingInNextTwelveMonths	12261392	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Two LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearTwo	43	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Two LifeSettlementContractsFairValueMethodFaceValueMaturingInYearTwo	47111084	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Two LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearTwo	44975920	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Two LifeSettlementContractsFairValueMaturingInYearTwo	24919807	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Three LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearThree	73	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Three LifeSettlementContractsFairValueMethodFaceValueMaturingInYearThree	154161274	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Three LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearThree	151400918	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear	7	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMethodFaceValueMaturingInRemainderOfFiscalYear	8100000	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Remainder Of Fiscal Year LifeSettlementContractFairValueMethodNetDeathBenefitMaturityRemainderOfFiscalYear	8100000	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMaturingInRemainderOfFiscalYear	6386561	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInNextTwelveMonths	15	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodFaceValueMaturingInNextTwelveMonths	16908593	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year One LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearOne	19557874	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMaturingInNextTwelveMonths	12261392	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Two LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearTwo	43	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Two LifeSettlementContractsFairValueMethodFaceValueMaturingInYearTwo	47111084	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Two LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearTwo	44975920	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Two LifeSettlementContractsFairValueMaturingInYearTwo	24919807	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Three LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearThree	73	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Three LifeSettlementContractsFairValueMethodFaceValueMaturingInYearThree	154161274	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Three LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearThree	151400918	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Three LifeSettlementContractsFairValueMaturingInYearThree	70656882	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Four LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFour	50	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Four LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFour	73898519	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Four LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearFour	74046019	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Four LifeSettlementContractsFairValueMaturingInYearFour	27566589	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Number Of Contracts Maturity After Year Four LifeSettlementContractFairValueMethodNumberOfContractsMaturityAfterYearFour	339	insurance_contract
CY2024Q3	abl	Life Settlement Contract Fair Value Method Face Value Maturity After Year Four LifeSettlementContractFairValueMethodFaceValueMaturityAfterYearFour	676582361	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity After Year Four LifeSettlementContractFairValueMethodNetDeathBenefitMaturityAfterYearFour	674962708	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Maturity After Year Four LifeSettlementContractFairValueMaturityAfterYearFour	131458262	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	527	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	976761831	usd
CY2024Q3	abl	Life Settlement Contracts Fair Value Method Net Death Benefit LifeSettlementContractsFairValueMethodNetDeathBenefit	973043439	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	273249493	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths	1	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths	625000	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Three LifeSettlementContractsFairValueMaturingInYearThree	70656882	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Four LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFour	50	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Four LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFour	73898519	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Four LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearFour	74046019	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Four LifeSettlementContractsFairValueMaturingInYearFour	27566589	usd
CY2024Q3	abl	Life Settlement Contract Fair Value Maturity After Year Four LifeSettlementContractFairValueMaturityAfterYearFour	131458262	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	527	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	976761831	usd
CY2024Q3	abl	Life Settlement Contracts Fair Value Method Net Death Benefit LifeSettlementContractsFairValueMethodNetDeathBenefit	973043439	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	273249493	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths	1	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths	625000	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Net Death Benefit Maturity Year One LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearOne	649595	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInNextTwelveMonths	329714	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo	1	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo	750000	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Net Death Benefit Maturity Year Two LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearTwo	750000	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Two LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearTwo	395649	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour	2	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour	750000	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Net Death Benefit Maturity Year Four LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearFour	750000	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Four LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearFour	330552	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Number Of Contracts Maturity After Year Four LifeSettlementContractInvestmentMethodNumberOfContractsMaturityAfterYearFour	1	insurance_contract
CY2024Q3	abl	Life Settlement Contract Investment Method Face Value Maturity After Year Four LifeSettlementContractInvestmentMethodFaceValueMaturityAfterYearFour	100000	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Net Death Benefit Maturity After Year Four LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityAfterYearFour	100330	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Amount Maturity After Year Four LifeSettlementContractInvestmentMethodAmountMaturityAfterYearFour	15257	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	5	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	2225000	usd
CY2024Q3	abl	Life Settlement Contracts Investment Method Net Death Benefit LifeSettlementContractsInvestmentMethodNetDeathBenefit	2249925	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1071172	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear	12804	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	57733	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	64043	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	37210	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour	15920	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Premium To Be Paid After Year Four LifeSettlementContractInvestmentMethodPremiumToBePaidAfterYearFour	17424	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Net Death Benefit Maturity Year One LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearOne	649595	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInNextTwelveMonths	329714	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo	1	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo	750000	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Net Death Benefit Maturity Year Two LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearTwo	750000	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Two LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearTwo	395649	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour	2	insurance_contract
CY2024Q3	abl	Life Settlement Contract Investment Method Net Death Benefit Maturity Year Four LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearFour	750000	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Number Of Contracts Maturity After Year Four LifeSettlementContractInvestmentMethodNumberOfContractsMaturityAfterYearFour	1	insurance_contract
CY2024Q3	abl	Life Settlement Contract Investment Method Face Value Maturity After Year Four LifeSettlementContractInvestmentMethodFaceValueMaturityAfterYearFour	100000	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Net Death Benefit Maturity After Year Four LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityAfterYearFour	100330	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Amount Maturity After Year Four LifeSettlementContractInvestmentMethodAmountMaturityAfterYearFour	15257	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	5	insurance_contract
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	2225000	usd
CY2024Q3	abl	Life Settlement Contracts Investment Method Net Death Benefit LifeSettlementContractsInvestmentMethodNetDeathBenefit	2249925	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1071172	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear	12804	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	57733	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	64043	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	37210	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour	15920	usd
CY2024Q3	abl	Life Settlement Contract Investment Method Premium To Be Paid After Year Four LifeSettlementContractInvestmentMethodPremiumToBePaidAfterYearFour	17424	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	205134	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1063941	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	470482	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	175422	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	69762	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	888519	usd
CY2024Q3	us-gaap	Depreciation Depreciation	46297	usd
	us-gaap	Depreciation Depreciation	14911	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	470482	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	175422	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	69762	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	888519	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	400720	usd
CY2023Q3	us-gaap	Depreciation Depreciation	12770	usd
	us-gaap	Depreciation Depreciation	105660	usd
	us-gaap	Depreciation Depreciation	14911	usd
CY2024Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	32900000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29300000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8410417	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20889583	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1682083	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1682083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5046250	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1682083	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1682083	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5328333	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3911667	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3895000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2635000	usd
CY2024Q3	abl	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	3437500	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20889583	usd
CY2024Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	163558	usd
CY2023Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	87297	usd
CY2024Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	32900000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29300000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8410417	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20889583	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1682083	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1682083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5046250	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1682083	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1682083	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5328333	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3911667	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3895000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2635000	usd
CY2024Q3	abl	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	3437500	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20889583	usd
CY2024Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	163558	usd
CY2023Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	87297	usd
CY2024Q3	abl	Debt Securities Available For Sale Principal Amount DebtSecuritiesAvailableForSalePrincipalAmount	1000000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.08
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1185740	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	185740	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	105935	usd
CY2024Q3	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	20165	usd
CY2023Q3	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	0	usd
	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	79805	usd
	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	0	usd
CY2024Q3	abl	Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld	2	entity
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1850000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1650000	usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1650698	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	998945	usd
CY2024Q3	abl	Debt Securities Available For Sale Principal Amount DebtSecuritiesAvailableForSalePrincipalAmount	1000000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.08
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1185740	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1105935	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	185740	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	105935	usd
CY2024Q3	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	20165	usd
CY2023Q3	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	0	usd
	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	79805	usd
	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	0	usd
CY2024Q3	abl	Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld	2	entity
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1850000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1650000	usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1650698	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	998945	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	3019055	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	2348998	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3019055	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2252891	usd
CY2024Q3	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	0	usd
CY2023Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	96107	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	3019055	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	2348998	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	3019055	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	2348998	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3019055	usd
CY2024Q3	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	0	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	2348998	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2024Q3	us-gaap	Revenues Revenues	28148491	usd
CY2023Q3	us-gaap	Revenues Revenues	21120930	usd
	us-gaap	Revenues Revenues	78711777	usd
	us-gaap	Revenues Revenues	42705904	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	2187981	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	3364957	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7652412	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4827907	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	17755973	usd
	us-gaap	Gross Profit GrossProfit	71059365	usd
	us-gaap	Gross Profit GrossProfit	37877997	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1704154	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6651942	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3116999	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15489503	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9838951	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2024Q3	us-gaap	Revenues Revenues	28148491	usd
CY2023Q3	us-gaap	Revenues Revenues	21120930	usd
	us-gaap	Revenues Revenues	78711777	usd
	us-gaap	Revenues Revenues	42705904	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	2187981	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	3364957	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7652412	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4827907	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	25960510	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	17755973	usd
	us-gaap	Gross Profit GrossProfit	71059365	usd
	us-gaap	Gross Profit GrossProfit	37877997	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2169197	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1704154	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6651942	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3116999	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15489503	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9838951	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41396346	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11113382	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1745279	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1694853	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5177785	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1696994	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9832	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20086	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	132610	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1565	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8766500	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41396346	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11113382	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1745279	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5177785	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9832	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	132610	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1565	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8487040	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2679237	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	12417946	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3620695	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	609496	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	63826	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1670828	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	71283	usd
CY2024Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-124237	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2088797	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-4036327	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-309865	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	417677	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-306800	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1220161	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	491356	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	856744	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-250368	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1710315	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2238419	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-159756	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	147611	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-339692	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-5125055	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	903361	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5703817	usd
	us-gaap	Net Income Loss NetIncomeLoss	15739009	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1071172	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8487040	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4218314	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2679237	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	12417946	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3620695	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	609496	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	63826	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1670828	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	71283	usd
CY2024Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-124237	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2088797	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-4036327	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-309865	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	417677	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-306800	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1220161	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	491356	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	856744	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-250368	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1710315	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2680855	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2238419	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-159756	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	147611	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-204716	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-339692	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5703817	usd
	us-gaap	Net Income Loss NetIncomeLoss	15739009	usd
CY2024Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1071172	usd
CY2023Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	1697178	usd
CY2024Q3	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	253146067	usd
	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	-20103426	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	273249493	usd
CY2024Q3	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	295143512	usd
	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	21894019	usd
CY2024Q3	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-181270	usd
CY2024Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	31603	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	75652	usd
CY2024Q3	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	10974	usd
	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	25104	usd
CY2024Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-124237	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-4036327	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	68348556	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	4040758	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-4036327	usd
	us-gaap	Fair Value Option Credit Risk Gains Losses On Assets FairValueOptionCreditRiskGainsLossesOnAssets	-101337	usd
	abl	Fair Value Option Credit Risk Gains Losses On Assets Included In Equity Attributable To Noncontrolling Interest FairValueOptionCreditRiskGainsLossesOnAssetsIncludedInEquityAttributableToNoncontrollingInterest	-33626	usd
	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-4171290	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	428276	usd
CY2024Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	110088766	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1185740	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1105935	usd
CY2024Q3	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	253146067	usd
	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	-20103426	usd
CY2024Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	273249493	usd
CY2024Q3	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	295143512	usd
	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	21894019	usd
CY2024Q3	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-181270	usd
	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-4171290	usd
CY2024Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	31603	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	75652	usd
CY2024Q3	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	10974	usd
	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	25104	usd
CY2024Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-124237	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-4036327	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	68348556	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	4040758	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-4036327	usd
	us-gaap	Fair Value Option Credit Risk Gains Losses On Assets FairValueOptionCreditRiskGainsLossesOnAssets	-101337	usd
	abl	Fair Value Option Credit Risk Gains Losses On Assets Included In Equity Attributable To Noncontrolling Interest FairValueOptionCreditRiskGainsLossesOnAssetsIncludedInEquityAttributableToNoncontrollingInterest	-33626	usd
	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-4171290	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	428276	usd
CY2024Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	110088766	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1185740	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1105935	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	abl	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75756439	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74708213	shares
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1048226	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62961688	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62961688	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63388823	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63242173	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	146650	shares
CY2023Q4	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	15000000	usd
CY2023Q4	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P18M
CY2024Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	2974863	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	146650	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1283062	usd
CY2023Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	8.82
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	316800	shares
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	3664552	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	11.61
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	200916	shares
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2480383	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	12.35
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	114400	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	abl	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75756439	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74708213	shares
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1048226	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62961688	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62961688	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63388823	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63242173	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	146650	shares
CY2024Q2	abl	Sale Of Stock Over Allotment Option Term SaleOfStockOverAllotmentOptionTerm	P30D
CY2023Q4	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	15000000	usd
CY2023Q4	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P18M
CY2024Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	2974863	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	146650	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1283062	usd
CY2023Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	8.82
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	316800	shares
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	3664552	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	11.61
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	200916	shares
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2480383	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	12.35
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	114400	shares
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1379457	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	12.06
CY2024Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	173197	shares
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1379457	usd
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	12.06
CY2024Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	173197	shares
CY2024Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2081859	usd
CY2024Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	12.02
CY2024Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	96263	shares
CY2024Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1135824	usd
CY2024Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	11.81
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1048226	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	12025137	usd
CY2024Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	11.61
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2300
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0398
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M21D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.91
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	345263	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.91
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	345263	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.91
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2024Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	102947	usd
CY2023Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	61586	usd
CY2024Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2081859	usd
CY2024Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	12.02
CY2024Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	96263	shares
CY2024Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1135824	usd
CY2024Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	11.81
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1048226	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	12025137	usd
CY2024Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	11.61
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2300
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0398
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M21D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.91
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	345263	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.91
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	345263	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.91
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2024Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	102947	usd
CY2023Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	61586	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	302479	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	86901	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-250368	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1710315	usd
CY2024Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.045
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.619
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2680855	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2238419	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.831
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.127
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	359352	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	302479	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	86901	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-250368	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1710315	usd
CY2024Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.045
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.619
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2680855	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2238419	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.831
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.127
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	359352	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2033538	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1893659	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	413071	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1860736	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1796727	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2273807	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1914785	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2033538	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1893659	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	413071	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118058	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1860736	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1796727	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2273807	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1914785	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	128607	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	69904	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	379047	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	94846	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	310231	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	20540	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	456477	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	29465	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	438838	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	90444	usd
	us-gaap	Lease Cost LeaseCost	124311	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	501994	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	96891	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	359352	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0967
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	69904	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	379047	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	20540	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	456477	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	29465	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	438838	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	90444	usd
	us-gaap	Lease Cost LeaseCost	835524	usd
	us-gaap	Lease Cost LeaseCost	124311	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	501994	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	96891	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	359352	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0967
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0342
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	0	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	553953	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	570602	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	587694	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	605268	usd
CY2024Q3	abl	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	623490	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2941007	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	667200	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2273807	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5125055	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	903361	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5703817	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15739009	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74694319	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63349823	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66984401	shares

Files In Submission

Name	View Source	Status
0001814287-24-000054-index-headers.html	Edgar Link	pending
0001814287-24-000054-index.html	Edgar Link	pending
0001814287-24-000054.txt	Edgar Link	pending
0001814287-24-000054-xbrl.zip	Edgar Link	pending
abl-20240930.htm	Edgar Link	pending
abl-20240930.xsd	Edgar Link	pending
abl-20240930_g1.jpg	Edgar Link	pending
exhibit211_ablsubsidiaries.htm	Edgar Link	pending
exhibit311_certxablxfs0930.htm	Edgar Link	pending
exhibit312_certxablxfs0930.htm	Edgar Link	pending
exhibit321_certxablxfs0930.htm	Edgar Link	pending
exhibit322_certxablxfs0930.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
abl-20240930_cal.xml	Edgar Link	unprocessable
abl-20240930_def.xml	Edgar Link	unprocessable
abl-20240930_lab.xml	Edgar Link	unprocessable
abl-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abl-20240930_htm.xml	Edgar Link	completed
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABL
Abacus Life, Inc. Stock $abl

2024 Q4 Form 10-Q Financial Statement

#000181428724000054 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABL Abacus Life, Inc. Stock $abl

2024 Q4 Form 10-Q Financial Statement

#000181428724000054 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABL
Abacus Life, Inc. Stock $abl